CCR4 and peripheral T-cell lymphoma, not otherwise specified: This drug was approved in Japan for CCR4-positive adult T cell leukemia/lymphoma (ATL) in 2012 [19], relapse/refractory CCR4-positive peripheral T cell lymphoma (PTCL) and CTCL in 2014.